新生儿代谢谱与儿童肾脏病的关联
在加拿大安大略省2006至2015年出生的1,288,905名新生儿中,利用常规新生儿代谢筛查谱分析其与儿童慢性肾脏病(CKD)或透析的关联。CKD发生2086例(0.16%),透析641例(0.05%)。加入代谢物后,CKD模型c统计量从0.61升至0.66,透析模型从0.70升至0.77,显示代谢谱可增量预测儿童肾脏病风险。
要点
- 常规新生儿代谢筛查谱与儿童CKD及透析需求相关。
- 加入代谢物可提升CKD和透析风险预测模型的区分度。
- 代谢谱为传统临床风险因素提供增量预测信息。
核心结论
- 新生儿常规筛查代谢物与儿童CKD及透析治疗需求相关,并为传统临床风险因素提供增量信息。
研究设计与样本
- 基于加拿大安大略省2006至2015年1,288,905名新生儿代谢谱的人群队列研究。
- 主要结局为CKD或透析,采用逻辑回归分析单个代谢物及其比值组合,并评估增量风险预测。
主要发现
- CKD发生2086例(0.16%,中位时间612天),透析641例(0.05%,中位时间99天)。
- 仅含临床风险因素的基线模型c统计量:CKD为0.61,透析为0.70。
- 加入代谢物后CKD模型c统计量0.66(NRI 0.36,IDI 0.04),透析模型c统计量0.77(NRI 0.57,IDI 0.09)。
- 内部验证(bootstrapping)及排除30天内结局的敏感性分析结果一致。
关键数值与推荐
- 代谢物包括氨基酸、酰基肉碱、脂肪酸氧化标志物等。
- 基线模型仅含临床风险因素时c统计量CKD 0.61、透析0.70。
- 加入代谢物后CKD模型c统计量0.66(NRI 0.36,IDI 0.04),透析模型c统计量0.77(NRI 0.57,IDI 0.09)。
临床怎么用
- 新生儿代谢筛查数据或可用于儿童肾脏病早期风险识别,但需外部验证。
- 在临床风险模型基础上加入代谢物可改善预测区分度与重分类。
局限性
- 仅内部验证(bootstrapping),未进行外部验证。
- 观察性设计,不能推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Metabolomics offers considerable promise in early disease detection. We set out to test the hypothesis that routine newborn metabolic profiles at birth, obtained through screening for inborn errors of metabolism, would be associated with kidney disease and add incremental information to known clinical risk factors. METHODS: We conducted a population-level cohort study in Ontario, Canada, using metabolic profiles from 1,288,905 newborns from 2006 to 2015. The primary outcome was chronic kidney disease (CKD) or dialysis. Individual metabolites and their ratio combinations were examined by logistic regression after adjustment for established risk factors for kidney disease and incremental risk prediction measured. RESULTS: CKD occurred in 2086 (0.16%, median time 612 days) and dialysis in 641 (0.05%, median time 99 days) infants and children. Individual metabolites consisted of amino acids, acylcarnitines, markers of fatty acid oxidation, and others. Base models incorporating clinical risk factors only provided c-statistics of 0.61 for CKD and 0.70 for dialysis. The addition of identified metabolites to risk prediciton models resulted in significant incremental improvement in the performance of both models (CKD model: c-statistic 0.66 NRI 0.36 IDI 0.04, dialysis model: c-statistic 0.77 NRI 0.57 IDI 0.09). This was consistent after internal validation using bootstrapping and a sensitivity analysis excluding outcomes within the first 30 days. CONCLUSION: Routinely collected screening metabolites at birth are associated with CKD and the need for dialytic therapies in infants and children, and add incremental information to traditional clinical risk factors.
引用
- Sood MM, Murphy MSQ, Hawken S, et al. Association Between Newborn Metabolic Profiles and Pediatric Kidney Disease. Kidney Int Rep. 2018. PMID: 29854978. doi:10.1016/j.ekir.2018.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。